Table 2—

Lung function and chronic obstructive pulmonary disease(COPD) prevalence according to stage and histology in the lung cancer cohort^#

Lung cancer histology^¶	Subjects n	Staging⁺	Spirometry				COPD prevalence GOLD 2+ %
Lung cancer histology^¶	Subjects n	Staging⁺	FEV₁ L	FEV₁ % pred	FVC L	FEV₁/FVC %	COPD prevalence GOLD 2+ %
Small cell^§	78		1.88±0.46	72±17	2.95±0.71	64±7	53
	26	Limited	1.81±0.63	72±19	2.86±0.77	63±12	50
	52	Extensive	1.92±0.44	73±17	3.00±0.71	64±7	54
Nonsmall cell^ƒ	100	Stage 1	1.89±0.72	78±27	2.87±0.83	66±15	46
	34	Stage 2	1.77±0.43	71±19	2.68±0.71	67±13	42
	107	Stage 3	2.11±0.33	76±10	3.23±0.52	65±14	46
	103	Stage 4	1.93±0.87	70±25	2.97±0.67	65±11	48
Histological subtype
Adenocarcinoma	191		1.96±0.65	77±26	2.96±0.44	66±13	45
Squamous	108		1.85±0.29	70±22	2.93±0.47	63±12	51
Nonsmall	45		1.78±0.55	71±19	2.89±0.87	62±11	47

Data are presented as mean±sd, unless otherwise stated. FEV₁: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease. ^#: n = 446; ^¶: histology not available in 5% of all lung cancer cases; ⁺: data for accurate staging was available in 85% of nonsmall cell lung cancer cases; ^§: total n = 78, 17%; ^ƒ: total n = 344, 77%.